We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
- Authors
Lee, Jin Soo; Hirsh, Vera; Park, Keunchil; Qin, Shukui; Blajman, Cesar R; Perng, Reury-Perng; Chen, Yuh-Min; Emerson, Laura; Langmuir, Peter; Manegold, Christian
- Abstract
Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 10, p1114
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.36.1709